Azzedine Yaici
Overview
Explore the profile of Azzedine Yaici including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
2234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Couturaud F, Schmidt J, Sanchez O, Ballerie A, Sevestre M, Meneveau N, et al.
Lancet
. 2025 Mar;
405(10480):725-735.
PMID: 40023651
Background: In patients with venous thromboembolism at high risk of recurrence for whom extended treatment with direct oral anticoagulants has been indicated, the optimal dose is unknown. We aimed to...
2.
Girerd B, Montani D, Jais X, Eyries M, Yaici A, Sztrymf B, et al.
Eur Respir J
. 2015 Dec;
47(2):541-52.
PMID: 26699722
Genetic causes of pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease (PVOD) have been identified, leading to a growing need for genetic counselling.Between 2003 and 2014, genetic counselling was offered...
3.
Cracowski J, Chabot F, Labarere J, Faure P, Degano B, Schwebel C, et al.
Eur Respir J
. 2013 Nov;
43(3):915-7.
PMID: 24232704
No abstract available.
4.
Lang I, Simonneau G, Pepke-Zaba J, Mayer E, Ambroz D, Blanco I, et al.
Thromb Haemost
. 2013 May;
110(1):83-91.
PMID: 23677493
Chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary hypertension (IPAH) share a similar clinical presentation, and a differential diagnosis requires a thorough workup. Once CTEPH is confirmed, patients who can...
5.
Cracowski J, Degano B, Chabot F, Labarere J, Schwedhelm E, Monneret D, et al.
Chest
. 2012 Mar;
142(4):869-876.
PMID: 22406961
Objectives: Within the past decade, biochemical markers have emerged as attractive tools to assess pulmonary arterial hypertension (PAH) prognosis, being noninvasive and easily repeatable.The objective of this study was to...
6.
Bussone G, Tamby M, Calzas C, Kherbeck N, Sahbatou Y, Sanson C, et al.
Ann Rheum Dis
. 2011 Nov;
71(4):596-605.
PMID: 22084393
Objectives: Pulmonary arterial hypertension (PAH) is characterised by remodelling of pulmonary arteries with enhanced vascular smooth muscle cell (VSMC) contraction, migration and proliferation. The authors investigated the presence of antibodies...
7.
Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al.
Arthritis Rheum
. 2011 Jul;
63(11):3522-30.
PMID: 21769843
Objective: Pulmonary arterial hypertension (PAH) is a severe, life-limiting complication of systemic sclerosis (SSc). Guidelines recommend early detection and management of SSc-PAH. However, little is known about the impact of...
8.
Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, et al.
N Engl J Med
. 2011 Jul;
365(1):44-53.
PMID: 21732836
Background: The prevalence and characteristics of pulmonary hypertension in adults with sickle cell disease have not been clearly established. Methods: In this prospective study, we evaluated 398 outpatients with sickle...
9.
OCallaghan D, Savale L, Yaici A, Natali D, Jais X, Parent F, et al.
Expert Opin Pharmacother
. 2011 Apr;
12(10):1585-96.
PMID: 21504371
Introduction: Endothelin is a key mediator in the pathophysiology of pulmonary arterial hypertension (PAH). Its effects are mediated through the activation of two associated receptor subtypes, termed A and B....
10.
Launay D, Humbert M, Berezne A, Cottin V, Allanore Y, Couderc L, et al.
Chest
. 2011 Apr;
140(4):1016-1024.
PMID: 21474572
Background: Pulmonary hypertension (PH) complicating systemic sclerosis (SSc)-related interstitial lung disease (ILD) is usually associated with a poor prognosis. However, data are either lacking or scarce on prognostic factors in...